ATE475671T1 - Antikörper gegen menschlichen nogo a und seine pharmazeutische verwendung - Google Patents

Antikörper gegen menschlichen nogo a und seine pharmazeutische verwendung

Info

Publication number
ATE475671T1
ATE475671T1 AT03782350T AT03782350T ATE475671T1 AT E475671 T1 ATE475671 T1 AT E475671T1 AT 03782350 T AT03782350 T AT 03782350T AT 03782350 T AT03782350 T AT 03782350T AT E475671 T1 ATE475671 T1 AT E475671T1
Authority
AT
Austria
Prior art keywords
human
antibodies
binding molecule
pharmaceutical use
human nogo
Prior art date
Application number
AT03782350T
Other languages
English (en)
Inventor
Carmen Barske
Anis Mir
Thomas Oertle
Lisa Schnell
Martin Schwab
Alessandra Vitaliti
Mauro Zurini
Original Assignee
Novartis Pharma Gmbh
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh, Univ Zuerich filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE475671T1 publication Critical patent/ATE475671T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03782350T 2002-12-10 2003-12-09 Antikörper gegen menschlichen nogo a und seine pharmazeutische verwendung ATE475671T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228832.2A GB0228832D0 (en) 2002-12-10 2002-12-10 Organic compound
PCT/EP2003/013960 WO2004052932A2 (en) 2002-12-10 2003-12-09 Antibody (“11c7”) anti nogo a and its pharmaceutical use

Publications (1)

Publication Number Publication Date
ATE475671T1 true ATE475671T1 (de) 2010-08-15

Family

ID=9949456

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03782350T ATE475671T1 (de) 2002-12-10 2003-12-09 Antikörper gegen menschlichen nogo a und seine pharmazeutische verwendung

Country Status (24)

Country Link
US (2) US7785593B2 (de)
EP (1) EP1572745B1 (de)
JP (1) JP4504200B2 (de)
KR (1) KR101215801B1 (de)
CN (1) CN100384877C (de)
AT (1) ATE475671T1 (de)
AU (1) AU2003289998B2 (de)
BR (1) BR0317161A (de)
CA (1) CA2509068C (de)
CY (1) CY1110848T1 (de)
DE (1) DE60333585D1 (de)
DK (1) DK1572745T3 (de)
EC (1) ECSP055849A (de)
ES (1) ES2349293T3 (de)
GB (1) GB0228832D0 (de)
IL (1) IL169018A (de)
MX (1) MXPA05006265A (de)
NO (1) NO20053304L (de)
PL (1) PL210720B1 (de)
PT (1) PT1572745E (de)
RU (1) RU2350623C2 (de)
SI (1) SI1572745T1 (de)
WO (1) WO2004052932A2 (de)
ZA (1) ZA200504522B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
EP2213684A3 (de) * 2003-12-22 2011-05-18 Glaxo Group Limited Nogo-A-Antikörper für die Behandlung von Alzheimer-Krankheit
HRP20120851T1 (hr) * 2005-07-05 2012-11-30 Glaxo Group Limited Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
MX2010004831A (es) * 2007-11-02 2010-05-21 Novartis Ag Moleculas de enlace de nogo-a mejoradas y uso farmaceutico de las mismas.
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
AU2013285493A1 (en) 2012-07-05 2015-01-22 Glaxo Group Limited Optimum dose regime of an anti-Nogo-A antibody in the treatment of amyotrophic lateral sclerosis
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2015002729A2 (en) * 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
EP4041392A1 (de) 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Antikörper gegen den poliovirus-rezeptor (pvr) und verwendungen davon
US20230399390A1 (en) 2019-10-24 2023-12-14 Novago Therapeutics Ag Novel anti-nogo-a antibodies
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0281604B1 (de) 1986-09-02 1993-03-31 Enzon Labs Inc. Bindungsmoleküle mit einzelpolypeptidkette
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
CA2082160C (en) * 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
JP2002522016A (ja) 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ
CN101684155A (zh) 1998-11-06 2010-03-31 苏黎世大学 Nogo基因的核苷酸序列和蛋白序列以及基于其的方法
CU22921A1 (es) 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
HK1051543A1 (zh) 2000-01-12 2003-08-08 Yale University Nogo受体介导的轴突生长封锁
EP2165714B1 (de) * 2001-04-30 2013-10-23 Eli Lilly And Company Humanisierte Antikörper die das Beta-Amyloid Peptid erkennen
DE20110806U1 (de) 2001-06-29 2001-12-20 Jack Wolfskin Ausrüstung für Draussen GmbH, 65510 Idstein Zelt
AR037456A1 (es) * 2001-11-30 2004-11-10 Biogen Inc Anticuerpos contra proteinas quimiotacticas monocitarias
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
EP2213684A3 (de) * 2003-12-22 2011-05-18 Glaxo Group Limited Nogo-A-Antikörper für die Behandlung von Alzheimer-Krankheit
US7596225B2 (en) * 2005-06-30 2009-09-29 Alcatl-Lucent Usa Inc. Method for refreshing a pairwise master key

Also Published As

Publication number Publication date
EP1572745B1 (de) 2010-07-28
ZA200504522B (en) 2006-03-29
US8535666B2 (en) 2013-09-17
SI1572745T1 (sl) 2010-12-31
DK1572745T3 (da) 2010-10-25
MXPA05006265A (es) 2005-12-05
RU2350623C2 (ru) 2009-03-27
WO2004052932A2 (en) 2004-06-24
US7785593B2 (en) 2010-08-31
WO2004052932A3 (en) 2004-10-21
PL377506A1 (pl) 2006-02-06
US20060183678A1 (en) 2006-08-17
ECSP055849A (es) 2005-09-20
JP2006523087A (ja) 2006-10-12
AU2003289998A1 (en) 2004-06-30
BR0317161A (pt) 2005-11-01
PT1572745E (pt) 2010-10-21
IL169018A (en) 2012-07-31
AU2003289998B2 (en) 2008-02-14
RU2005121669A (ru) 2007-01-20
EP1572745A2 (de) 2005-09-14
KR20050095768A (ko) 2005-09-30
HK1084676A1 (en) 2006-08-04
PL210720B1 (pl) 2012-02-29
GB0228832D0 (en) 2003-01-15
CN1747971A (zh) 2006-03-15
DE60333585D1 (de) 2010-09-09
ES2349293T3 (es) 2010-12-29
CA2509068A1 (en) 2004-06-24
NO20053304L (no) 2005-09-07
US20110059110A1 (en) 2011-03-10
NO20053304D0 (no) 2005-07-06
CA2509068C (en) 2012-02-07
CN100384877C (zh) 2008-04-30
CY1110848T1 (el) 2015-06-10
JP4504200B2 (ja) 2010-07-14
KR101215801B1 (ko) 2012-12-26

Similar Documents

Publication Publication Date Title
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
ECSP056263A (es) Anticuerpos humanizados que reconocen el péptido beta amiloideo
ATE440825T1 (de) Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
DE602005026219D1 (de) Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
CY1115014T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΕΙΔΙΚΑ ΓΙΑ Αβ1-42 ΜΕ ΘΕΡΑΠΕΥΤΙΚΕΣ ΙΔΙΟΤΗΤΕΣ
ATE506072T1 (de) Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
DE60032486D1 (de) Prion protein peptide und deren verwendung
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
DK2004688T4 (da) Forbedrede selektive protofibrille antistoffer og anvendelsen deraf
EA200700136A1 (ru) Анти-cd154-антитела
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
Garcia-Ferrer et al. Structural and functional insights into Escherichia coli α2-macroglobulin endopeptidase snap-trap inhibition
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
BRPI0414174B8 (pt) anticorpos ou fragmentos de ligação a antígeno do mesmo uso dos mesmos, polinucleotídeo, vetor, sistema de expressão, e composição farmacêutica.
TH71697A (th) โมเลกุลสำหรับจับ nogo-a และการใช้สารเหล่านี้ในทางยา
DE60322259D1 (de) Asthma-empfindlichkeitsort

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1572745

Country of ref document: EP